ES2061850T3 - Virus recombinante de la enfermedad de marek, su procedimiento de preparacion y vacuna. - Google Patents

Virus recombinante de la enfermedad de marek, su procedimiento de preparacion y vacuna.

Info

Publication number
ES2061850T3
ES2061850T3 ES89116679T ES89116679T ES2061850T3 ES 2061850 T3 ES2061850 T3 ES 2061850T3 ES 89116679 T ES89116679 T ES 89116679T ES 89116679 T ES89116679 T ES 89116679T ES 2061850 T3 ES2061850 T3 ES 2061850T3
Authority
ES
Spain
Prior art keywords
marek
fragment
virus
animal
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89116679T
Other languages
English (en)
Inventor
Masashi Sakaguchi
Hiroaki Maeda
Michitaka Yamamoto
Junichi Higashimachi Miyazaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Sero Therapeutic Research Institute Kaketsuken
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeutic Research Institute Kaketsuken filed Critical Chemo Sero Therapeutic Research Institute Kaketsuken
Application granted granted Critical
Publication of ES2061850T3 publication Critical patent/ES2061850T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/255—Marek's disease virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE DESCRIBE UNA MODIFICACION DEL MAL DE MAREK, LA CUAL COMPRENDE LA ESTRUCTURA COMPLETA DEL VIRUS DEL MAL DE MAREK Y UN FRAGMENTO DE DNA INCORPORADO A ELLA, CONTENIENDO DICHO FRAGMENTO DE DNA UN PORTADOR DERIVADO DE UNA CELULA ANIMAL O DE UN VIRUS ANIMAL Y UNA ESTRUCTURA DE GENE CODIFICADA PARA UNA PROTEINA EXOGENA. ADICIONALMENTE SE DESCRIBE UN PROCESO PARA PREPARAR DICHO VIRUS MODIFICADO, EL CUAL COMPRENDE PREPARAR UN FRAGMENTO DE GENE EN DONDE UNA CODIFICACION DE ESTRUCTURA GENETICA PARA UN GEN EXOGENO SE LOCALIZA CADENA ABAJO DE UN PORTADOR DERIVADO DE UNA CELULA ANIMAL O DE UN VIRUS ANIMAL, INCORPORANDO DICHO FRAGMENTO DE GEN EL FRAGMENTO BAMHL-H DE UN GEN DEL VIRUS DE LA ENFERMEDAD DE MAREK DE TIPO I, E INCORPORANDO DICHO FRAGMENTO UN VIRUS DE LA ENFERMEDAD DE MAREK TIPO I COMPLETO. FINALMENTE SE DESCRIBE UNA VACUNA ACTIVA POLIVALENTE PARA PAJAROS, LA CUAL CONTIENE EL VIRUS ANTERIOR MODIFICADO.
ES89116679T 1988-09-10 1989-09-08 Virus recombinante de la enfermedad de marek, su procedimiento de preparacion y vacuna. Expired - Lifetime ES2061850T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP63226960A JP2583115B2 (ja) 1988-09-10 1988-09-10 組換えマレック病ウイルスおよびその製法

Publications (1)

Publication Number Publication Date
ES2061850T3 true ES2061850T3 (es) 1994-12-16

Family

ID=16853319

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89116679T Expired - Lifetime ES2061850T3 (es) 1988-09-10 1989-09-08 Virus recombinante de la enfermedad de marek, su procedimiento de preparacion y vacuna.

Country Status (7)

Country Link
US (1) US5171677A (es)
EP (1) EP0361182B1 (es)
JP (1) JP2583115B2 (es)
AT (1) ATE100495T1 (es)
CA (1) CA1339774C (es)
DE (1) DE68912478T2 (es)
ES (1) ES2061850T3 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634636A (en) * 1983-12-13 1987-01-06 Asahi Kasei Kogyo Kabushiki Kaisha Polyacetylene composite
US5928648A (en) * 1985-09-06 1999-07-27 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
US5961982A (en) * 1985-09-06 1999-10-05 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
US5965138A (en) * 1985-09-06 1999-10-12 Syntro Corporation Recombinant chimeric virus and uses thereof
NL9001828A (nl) * 1990-08-15 1992-03-02 Centraal Diergeneeskundig Inst Werkwijze voor het wijzigen van het cel-, weefsel- of gastheertropisme van een microoerganisme; aldus verkregen gerecombineerd microorganisme en toepassing daarvan in de geneeskunde en diergeneeskunde.
AU657144B2 (en) * 1991-07-09 1995-03-02 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Recombinant Marek's disease virus, process for preparing the same and vaccine containing the same
US5853733A (en) * 1993-02-26 1998-12-29 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
JPH09508005A (ja) * 1994-01-11 1997-08-19 コーネル リサーチ ファンデーション インコーポレイテッド 潜伏と腫瘍細胞発生の阻害によるマレク病の抑制
FR2728795B1 (fr) * 1994-12-30 1997-03-21 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
JPH08322559A (ja) * 1995-06-02 1996-12-10 Chemo Sero Therapeut Res Inst ｇＢ遺伝子プロモーターを用いた組換えヘルペスウイルス

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US128836A (en) * 1872-07-09 Improvement in draught-regulators
EP0231209B1 (en) * 1985-07-29 1991-02-06 The Upjohn Company Virus vaccine
EP0256092B1 (en) * 1986-01-27 1998-04-08 Syntro Corporation Attenuated herpesviruses, herpesviruses which include foreign dna encoding an amino acid sequence and vaccine containing same
WO1988007088A1 (en) * 1987-03-19 1988-09-22 Synergen, Inc. Viral vector system for the introduction of foreign dna expression products into gallinaceous birds
AU628294B2 (en) * 1987-07-27 1992-09-17 Syntro Corporation Attenuated herpes viruses, herpes viruses which include foreign dna encoding an amino acid sequence and vaccines containing same
JP2779447B2 (ja) * 1988-03-20 1998-07-23 財団法人阪大微生物病研究会 弱毒マレック病ウイルス・ベクターを用いる組換え遺伝子作成法、及び該ウイルスの組換え体

Also Published As

Publication number Publication date
DE68912478D1 (de) 1994-03-03
EP0361182A1 (en) 1990-04-04
CA1339774C (en) 1998-03-24
JPH0276578A (ja) 1990-03-15
DE68912478T2 (de) 1994-05-11
ATE100495T1 (de) 1994-02-15
JP2583115B2 (ja) 1997-02-19
US5171677A (en) 1992-12-15
EP0361182B1 (en) 1994-01-19

Similar Documents

Publication Publication Date Title
ES2075901T3 (es) Sistemas de expresion de virus recombinantes de arn con cadena negativa y vacunas.
EA200401405A1 (ru) Модифицированный осповакцинный вирус анкара для вакцинации новорожденных
CO4750842A1 (es) Pox virus recombinantes de mapache y vacuna eficaz contra la infeccion del virus de inmunodeficiencia felina .
ES2143507T3 (es) Vacunas contra la enfermedad de aujeszky y de otras enfermedades animales que contienen mutantes del virus de la pseudorrabia.
ES2099066T3 (es) Antigenos a partir de adn sintetico derivado del virus de la inmunodeficiencia humana (hiv-1).
ATE115187T1 (de) Poxvirus-vektoren.
ES2061850T3 (es) Virus recombinante de la enfermedad de marek, su procedimiento de preparacion y vacuna.
UY24430A1 (es) Procedimiento para preparar vacuna contra tumores
MX9202512A (es) Virus de avipox recombinante, cultivo de celulas infectadas por este virusy vacunas para las aves de corral derivadas de este virus.
ES2066842T3 (es) Virus recombinante de la enfermedad de marek y vacuna.
DE3853139D1 (de) Rekombinanter, fremde gene enthaltender menschlicher cytomegalovirus und seine verwendung.
RU2002100209A (ru) Gm-csf лошади
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
AU6683400A (en) Vaccine against lentiviral infections, such as the feline immune deficiency virus of the cat
DK498387D0 (da) Virus-dna-sekvens
DK285986D0 (da) Proteiner af typen human che samt fremgangsmaade til fremstilling heraf
DE3789525D1 (de) Das F-Protein vom AIDS-Virus enthaltender Impfstoff.
ATE136933T1 (de) Rekombinante hbsag hybridpartikel, die morphologische eigenschaften von hbsag-antigen haben und eine immunogene sequenz enthalten, die neutralisierende antikörper gegen hiv induziert oder die von diesen antikörpern erkannt ist, nukleotide sequenzen, die diese partikel codieren und sie enthaltende impfstoffe
DE69233004D1 (de) Rekombinanter Virus der Marek-Krankheit, Verfahren zur Herstellung dieses Viruses und diesen enthaltender Impfstoff
WO1995005460A3 (en) Feline immunodeficiency virus isolate ncsu 1
KR930701588A (ko) 재조합 구두 바이러스 백신
Centers for Disease Control and Prevention (CDC Availability of new rabies vaccine for human use
ATE87977T1 (de) Herstellung menschlichen somatomedins c.
DE3789545D1 (de) Impfstoff bestehend aus einem Virusvektor und Rekombinanten-DNS, die das p25-Protein vom AIDS-Virus kodieren.
JPS6485072A (en) Recombinant vaccinia virus

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 361182

Country of ref document: ES